Q&A with Dr Martin Hall Analyst at Hardman & Co: Advanced Oncotherapy (LON:AVO)
10th October 2017
Hardman and Co’s Dr Martin Hall discusses Advanced Oncotherapy PLC in this exclusive interview with DirectorsTalk
Hardman and Co’s Dr Martin Hall discusses Advanced Oncotherapy PLC in this exclusive interview with DirectorsTalk
Advanced Oncotherapy plc (LON:AVO), Executive Chairman, Mike Sinclair provides an insight into his background in healthcare, his vision for AVO and the opportunity the Company has to transform the global
Advanced Oncotherapy Plc (LON:AVO) is the topic of conversation when Hardman & Co Analyst Dr Martin Hall caught up with DirectorsTalk. Martin shares his thoughts on the latest interims, explains
Advanced Oncotherapy Plc (LON:AVO) is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world renowned CERN. The company is entering an
Advanced Oncotherapy (LON:AVO), the developer of a next generation proton therapy system for cancer treatment, announced this morning its unaudited results for the six months ended 30 June 2017 and
If cost was not an issue, proton therapy would be the treatment of choice for most patients with localized tumours. Protons can be targeted more precisely than X-rays, so the
Advanced Oncotherapy plc (LON:AVO) Chief Operating Officer Ed Lee talks to DirectorsTalk about his background, what that experience brings to AVO and how that knowledge can translate into shareholder value.
According to the US National Cancer Institute, nearly 40 percent of Americans will be diagnosed with cancer during their lives. The World Health Organization names cancer as the second leading
Nicolas Serandour, CEO of Advanced Oncotherapy PLC (LON:AVO), talks to BRR Media about the details of the technological update and it representing significant progress in validating the capabilities of the
Advanced Oncotherapy (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced this morning that it remains on schedule with the development of the first LIGHT system, with
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
